lixisenatide (Adlyxin, Lyxumia)

From Aaushi
Jump to navigation Jump to search

Indications

* in patients with type 2 diabetes & recent acute coronary syndrome, lixisenatide did not significantly affect risk of major cardiovascular events[2]

Dosage

  • start 10 ug QD for 14 days, then increase to 20 ug QD

disposable prefilled syringes

Adverse effects

Mechanism of action

More general terms

Component of

References

  1. 1.0 1.1 GLP-1 Agonist Lixisenatide (Adlyxin) Okayed for Type 2 Diabetes in US. Medscape. Jul 28, 2016. http://www.medscape.com/viewarticle/866766
    FDA News Release. Jul 28, 2016 FDA approves Adlyxin to treat type 2 diabetes http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm513602.htm
  2. 2.0 2.1 Pfeffer MA, Claggett B, Diaz R et al for the ELIXA Investigators. Lixisenatide in Patients with Type 2 Diabetes and Acute Coronary Syndrome. N Engl J Med. 2015 Dec 3;373(23):2247-57. PMID: https://www.ncbi.nlm.nih.gov/pubmed/26630143
  3. 3.0 3.1 3.2 Adam D Diabetes drug slows development of Parkinson's disease. Nature News. April 3, 2024 https://www.nature.com/articles/d41586-024-00974-0
    Meissner WG et al Trial of Lixisenatide in Early Parkinson's Disease. N Engl J Med 2024;390:1176-1185 PMID: https://www.ncbi.nlm.nih.gov/pubmed/38598572 https://www.nejm.org/doi/full/10.1056/NEJMoa2312323

Database